Abstract:Over the past decade, there has been growing interest in the use of antibodies against intracellular targets. This is currently achieved through recombinant expression of the single chain variable fragment (scFv) antibody format within the cell, which is commonly referred to as an intrabody. This possesses a number of inherent advantages over RNA interference (iRNA). Firstly, the high specificity and affinity of intrabodies to target antigens is well-established, whereas iRNA has been frequently shown to exert multiple non-specific effects. Secondly, intrabodies being proteins possess a much longer active half-life compared to iRNA. Thirdly, when the active half-life of the intracellular target molecule is long, gene silencing through iRNA would be slow to yield any effect, whereas the effects of intrabody expression would be almost instantaneous. Lastly, it is possible to design intrabodies to block certain binding interactions of a particular target molecule, while sparing others. There is, however, various technical challenges faced with intrabody expression through the application of recombinant DNA technology. In particular, protein conformational folding and structural stability of the newly-synthesized intrabody within the cell is affected by reducing conditions of the intracellular environment. Also, there are overwhelming safety concerns surrounding the application of transfected recombinant DNA in human clinical therapy, which is required to achieve intrabody expression within the cell. Of particular concern are the various viral-based vectors that are commonly-used in genetic manipulation. A novel approach around these problems would be to look at the possibility of fusing protein transduction domains (PTD) to scFv antibodies, to create a ‘cell-permeable’ antibody or ‘Transbody’. PTD are short peptide sequences that enable proteins to translocate across the cell membrane and be internalized within the cytosol, through atypical secretory and internalization pathways. There are a number of distinct advantages that a ‘Transbody’ would possess over conventional intrabodies expressed within the cell. For a start, ‘correct’ conformational folding and disulfide bond formation can take place prior to introduction into the target cell. More importantly, the use of cell-permeable antibodies or ‘Transbodies’ would avoid the overwhelming safety and ethical concerns surrounding the direct application of recombinant DNA technology in human clinical therapy, which is required for intrabody expression within the cell. ‘Transbodies’ introduced into the cell would possess only a limited active half-life, without resulting in any permanent genetic alteration. This would allay any safety concerns with regards to their application in human clinical therapy.

Accumulation of antibody fusion proteins in the cytoplasm and ER of plant cells

Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: Potential advantages over antibodies expressed within the intracellular environment (Intrabody)

Optimization of scFv antibody production in transgenic plants

Production of Soluble and Functional Engineered Antibodies in Escherichia Coli Improved by Fkpa

Improving Expression of scFv Fragments by Co-expression of Periplasmic Chaperones

Engineering Production of Functional Scfv Antibody in E. Coli by Co-Expressing the Molecule Chaperone Skp

Intracellular expression of TMV-specific single-chain Fv fragments leads to improved virus resistance in shape Nicotiana tabacum

Affinity-purification of a TMV-specific recombinant full-size antibody from a transgenic tobacco suspension culture

Multimerization of peptide antigens for production of stable immunogens in transgenic plants

Soluble Expression and Purification of a Novel Single-Chain Fv Antibody Against Connective Tissue Growth Factor(ctgf/ccn2)

The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules

Expression of bioactive anti-CD20 antibody fragments and induction of ER stress response in Arabidopsis seeds

Identification of factors impeding the production of a single-chain antibody fragment in Escherichia coli by comparing in vivo and in vitro expression

Soluble expression of single-chain variable fragment (scFv) in Escherichia coli using superfolder green fluorescent protein as fusion partner

Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface.

Synthesis of single‐chain antibody fragment fused to the elastin‐like polypeptide in Nicotiana benthamiana and its application in affinity precipitation of difficult to produce proteins

High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli

Induction of protein body formation in plant leaves by elastin-like polypeptide fusions

Cell-free eukaryotic systems for the production, engineering, and modification of scFv antibody fragments

Expression of Recombinant Antibody scFv-GCN4 in Escherichia coli and Determination of its Biological Activity

Expression and Secretion of a CB4-1 Scfv–gfp Fusion Protein by Fission Yeast